COMP <GO>
ARVN vs PBYI // DIVIDEND YIELD & FCF PAYOUT SAFETY
Arvinas Inc. (NASDAQ) VS. Puma Biotechnology Inc (NASDAQ) • 15-METRIC TALLY: ARVN 2
— PBYI 5
■ METRIC PARITY
LAST: $7.90 (+3.95%) • MKT CAP: $516.6M
dividend-safety
0.00%
LAST: $10.54 (-0.75%) • MKT CAP: $544.1M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARVN VS. PBYI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARVN | PBYI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.10% | 29.30% | -61.40 | PBYI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 7.67% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -45.10% | 16.30% | -61.40 | PBYI | /operating-margins <GO> |
| Net Profit Margin | -30.80% | 13.60% | -44.40 | PBYI | /net-margins <GO> |
| Revenue Growth (YoY) | -0.30% | -0.90% | +0.60 | ARVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | PBYI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 52.9 | +1.66 | ARVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 16.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $516.6M | $544.1M | -$27.5M | PBYI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARVN REV | PBYI REV | ARVN GROSS % | PBYI GROSS % | ARVN FCF | PBYI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $262.6M | $228.4M | — | 74.5% | -$275.7M | $41.7M |
| FY 2024 | $263.4M | $230.5M | — | 72.1% | -$261.1M | $38.9M |
| FY 2023 | $78.5M | $235.6M | — | — | -$347.8M | $27.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARVN // BETA —
PBYI // BETA —